Who Optimizes SG&A Costs Better? Zoetis Inc. or Novavax, Inc.

Optimizing SG&A Costs: A Tale of Two Companies

In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Zoetis Inc. and Novavax, Inc. have taken distinct paths in optimizing these costs. From 2014 to 2023, Zoetis Inc. consistently maintained higher SG&A expenses, peaking at approximately $2.15 billion in 2023. This reflects their expansive operations and robust market presence. In contrast, Novavax, Inc. saw a significant increase in SG&A expenses, rising from around $20 million in 2014 to nearly $489 million in 2022, marking a staggering 2,345% increase. This surge aligns with their aggressive growth strategy and increased market activities. While Zoetis Inc. demonstrates stability, Novavax, Inc.'s rapid escalation in expenses highlights their dynamic approach in a volatile market. Understanding these trends offers valuable insights into each company's strategic priorities and market positioning.